Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Liabilities: 2018-2024

Historic Other Non-Current Liabilities for Zevra Therapeutics (ZVRA) over the last 7 years, with Dec 2024 value amounting to $14.4 million.

  • Zevra Therapeutics' Other Non-Current Liabilities rose 216.32% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 216.32%. This contributed to the annual value of $14.4 million for FY2024, which is 93.50% up from last year.
  • Per Zevra Therapeutics' latest filing, its Other Non-Current Liabilities stood at $14.4 million for FY2024, which was up 93.50% from $7.5 million recorded in FY2023.
  • Zevra Therapeutics' Other Non-Current Liabilities' 5-year high stood at $14.4 million during FY2024, with a 5-year trough of $25,000 in FY2022.
  • In the last 3 years, Zevra Therapeutics' Other Non-Current Liabilities had a median value of $7.5 million in 2023 and averaged $7.3 million.
  • Per our database at Business Quant, Zevra Therapeutics' Other Non-Current Liabilities slumped by 78.62% in 2021 and then skyrocketed by 29,732.00% in 2023.
  • Zevra Therapeutics' Other Non-Current Liabilities (Yearly) stood at $145,000 in 2020, then tumbled by 78.62% to $31,000 in 2021, then declined by 19.35% to $25,000 in 2022, then spiked by 29,732.00% to $7.5 million in 2023, then spiked by 93.50% to $14.4 million in 2024.